NIVOLUMAB for Prostate cancer: Side Effects & Safety Data
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
There are 317 adverse event reports in the FDA FAERS database where NIVOLUMAB was used for Prostate cancer.
Most Reported Side Effects for NIVOLUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 11,216 | 12.8% | 11,211 | 780 |
| Malignant neoplasm progression | 9,363 | 10.7% | 5,146 | 4,330 |
| Off label use | 5,208 | 5.9% | 1,240 | 1,725 |
| Diarrhoea | 4,692 | 5.4% | 623 | 2,506 |
| Fatigue | 3,709 | 4.2% | 409 | 1,425 |
| Pyrexia | 3,454 | 3.9% | 532 | 2,501 |
| Intentional product use issue | 3,297 | 3.8% | 1,461 | 827 |
| Rash | 2,816 | 3.2% | 297 | 1,131 |
| Nausea | 2,805 | 3.2% | 378 | 1,495 |
| Decreased appetite | 2,619 | 3.0% | 452 | 1,429 |
| Dyspnoea | 2,527 | 2.9% | 596 | 1,575 |
| Pneumonia | 2,281 | 2.6% | 792 | 1,676 |
| Colitis | 2,123 | 2.4% | 333 | 1,306 |
| Pneumonitis | 2,076 | 2.4% | 564 | 1,130 |
| Hypothyroidism | 1,939 | 2.2% | 267 | 946 |
Other Indications for NIVOLUMAB
Product used for unknown indication (12,733)
Malignant melanoma (10,599)
Non-small cell lung cancer (9,987)
Renal cell carcinoma (6,514)
Metastatic malignant melanoma (4,628)
Lung neoplasm malignant (4,197)
Metastatic renal cell carcinoma (3,857)
Gastric cancer (3,856)
Non-small cell lung cancer recurrent (2,703)
Renal cancer (1,756)
Other Drugs Used for Prostate cancer
LEUPROLIDE (45,399)
ENZALUTAMIDE (25,954)
RELUGOLIX (18,752)
ABIRATERONE (12,209)
APALUTAMIDE (3,286)
GOSERELIN (2,080)
DEGARELIX (2,035)
BICALUTAMIDE (1,832)
SIPULEUCEL-T (1,720)
DENOSUMAB (1,627)